Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02360579
Title Study of LN-144, Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma (LN-144)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Iovance Biotherapeutics, Inc.
Indications

melanoma

Therapies

LN-144

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.